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ABSTRACT: Modern combinatorial chemistry is used to discover compounds
with desired function by an alternative strategy, in which the biological target is
directly involved in the choice of ligands assembled from a pool of smaller
fragments. Herein, we present the ﬁrst experimental result where the use of in situ
click chemistry has been successfully applied to probe the ligand-binding site of Abl
and the ability of this enzyme to form its inhibitor. Docking studies show that Abl
is able to allow the in situ click chemistry between speciﬁc azide and alkyne
fragments by binding to Abl-active sites. This report allows medicinal chemists to
use protein-directed in situ click chemistry for exploring the conformational space
of a ligand-binding pocket and the ability of the protein to guide its inhibitor. This
approach can be a novel, valuable tool to guide drug design synthesis in the ﬁeld of
tyrosine kinases.
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The ﬁndings that Bcr-Abl (cytoplasmic tyrosine kinase) isthe cause of the leukemic phenotype and that the tyrosine
kinase activity of Abl is fundamental for Bcr-Abl-mediated
transformation have made this kinase an important target for
the development of speciﬁc therapies. In the recent past,
advances in the selective inhibition of Bcr-Abl kinase activity led
to the development of several active compounds, and in
particular, imatinib mesylate (Gleevec) is the one that currently
represents the front-line therapy of CML. Considering our
interest in the discovery of new inhibitors of tyrosine
kinases,1−5 we have recently reported the design and
preparation of a small collection of quality N-[2-methyl-5-
(triazol-1-yl)phenyl]pyrimidin-2-amine derivatives.6 The anti-
proliferative activity in the micromolar range pointed out the
eﬃcacy of the compound named FA030 (Figure 1, IC50 = 0.89
μM on the K-562 cell line). This one showed a potent
antienzymatic activity against recombinant Abl kinase (IC50 =
0.9 ± 0.1 μM). The ADME prediction suggested no signiﬁcant
diﬀerence between the behavior exhibited by FA030 and that of
imatinib that diﬀers for an amide group in the place of the
triazole ring.6 Moreover, the binding mode was very similar to
that of imatinib. FA030 seems to have six hydrogen bonds with
the protein, and the majority of contacts are mediated by van
der Waals interactions. The triazole ring is involved in two
hydrogen bonds with the carbonyl groups of Asp 381 and His
361.
Over the last years, target-guided in situ synthesis7 has
attracted our attention because it proved to be a captivating and
eﬃcient approach to drug discovery. We applied this strategy to
the formation of bivalent compounds that are able to target the
tubulin/microtubules dynamic system.8
Thus, we successfully used tubulin as a target to inﬂuence the
composition of the mixture of a dynamic combinatorial library
by exploiting the disulﬁde bond exchange reaction.9 In this
scenario, we turned our attention to in situ click chemistry10
based on Huisgen reaction,11−33 which we considered attractive
and stimulating for constructing inhibitors of tyrosine kinases
strategic for ﬁghting cancer. We were driven by the
antienzymatic activity and docking records of FA030. Thus,
we took into consideration the possible use of Abl as a target
for in situ click chemistry.
To investigate the ability of the azide 26 and alkyne 46
fragments to bind to the active site in a way that allows the click
reaction to occur, docking simulations were performed using
the docking program Glide.34 At ﬁrst, the azide was docked in
the ATP-binding site of Abl. The result of docking simulation is
shown in the Supporting Information. As we expected, the
fragment forms the same hydrogen bonds of FA030 with
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Met318 and Thr315, and the azide group is located in a
proﬁtable way near the triazole binding region of FA030. Then,
the alkyne fragment was docked considering the azide as part of
the receptor. The result of docking is shown in Figure 2. The
alkyne group is placed not far from the azide reactive group; the
distance is less than 5 Å. On the basis of our theoretical studies,
it is possible to assume that the two fragments can bind to the
active site of Abl, allowing the click reaction to take place.
First, we evaluated the ability of Abl (∼135 KDa, purity
>70%) to favor the formation of FA030 through click reaction
of azide 2 and alkyne 4. Two diﬀerent concentrations for the
reagents (0.25 and 0.370 μM) as well as for Abl tyrosine kinase
(0.0185 and 0.370 μM) were used in phosphate buﬀer (Table
1) and compared with the respective control solutions lacking
of Abl.
The presence of FA030 was checked with an ICP-FT-MS
instrument that permits the isotopic mass measurement with
little ppm error and has a resolution within the range of
15.000−5.000. We were fascinated with detecting the peak of
the target compound FA030, after 4 days, in both solutions
containing Abl (Figure 3a). The presence of FA030 was also
conﬁrmed by HPLC analysis (Figure 3b,d), using a RP column.
To exclude any possible catalytic activity due to the
unexpected presence of copper (buﬀer solutions), we analyzed,
using ICP-MS, the control and test solutions, and we compared
the values with the amount of Cu(I) generally used in the
Sharpless conditions6 (Table 2). The preparation of FA030
according to Sharpless conditions requires 1−5% (mol) of
Cu(II) that is reduced in situ to Cu(I) by sodium ascorbate. We
detected a low amount of copper in the control and test
solutions (Table 2, 0.1 and 0.04%, respectively). Besides, it is
Figure 1. Kinetic Abl-guided synthesis of FA030 via Huisgen 1,3-
dipolar cycloaddition.
Figure 2. Azide 2 and alkyne 4 docked in the Abl binding site.
Table 1. Concentration of Azide 2, Alkyne 4, and Abl in the
Reaction Mixture Maintained at 37 °C for 4 Days and
Detection of FA030 by Mass Spectroscopy
entry [azide 2] (μM) [alkyne 4] (μM) [Abl] (μM) HR-ESI
1 0.25 0.25 0.0185 518.27997a
2 0.25 0.25 0 no detection
3 370 370 0.37 518.27868b
4 370 370 0 no detection
aError (ppm), 4.7. bError (ppm), 2.2.
Figure 3. (a) FT-HRESI with the peak of FA030 (error, 4.7 ppm). (b)
HPLC method (X Briedge Shield RP18; 5 μm; 4.6 mm × 150 mm;
gradient CH3CN; from 20 to 50% in 20 min; 0.1 M phosphate buﬀer
at pH 7; column T = 40 °C; ﬂow, 1 mL/min; λ = 250 nm). (c)
Experimental vessel containing Abl and the building blocks. (d) HPLC
proﬁles of the solution with Abl (0.37 μM, blue line) and control (red
line).
Table 2. Detection by ICP-MS of Cu (Molar Ratio) in
Reaction Mixtures
azides alkynes Cu T (°C)
Sharpless cond. 1 1 0.01−0.05 25−120
Abl in situ 1 1 0.0017 37
control 1 1 0.00044 37
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reasonably in the oxidized form and thus not able to act as a
catalyst. In the test solution, we also detected Mn (0.007%), Co
(0.006%), Ni (0.27%), Zn (0.38%), and Pb (0.006%).
Having obtained this challenging result, we proved that Abl
has the capacity to favor click reaction between azide 2 and
alkyne 4. Subsequently, we moved toward the investigation of
Abl eﬃcacy in the selected target-catalyzed formation of FA030
from a library of building blocks that were simultaneously
present in a single reaction mixture. To that eﬀect, a solution of
azides 2 and 3 and alkynes 4−8 (370 μM) was incubated for 4
days, at 37 °C, in the presence of Abl (0.37 μM), in buﬀer
solution (Figure 3c). In addition to that, a control solution was
prepared without the tyrosine kinase. The use of HPLC and
HRESI MS evidenced only the peak generated by FA030,
without any trace of the other possible compounds that we
know to be ineﬀective in the inhibition of Abl activity. The
control solution did not show any detectable peak. We can
conﬁrm that Abl is able to selectively favor the formation of the
best inhibitor.
The results obtained conﬁrm the relevance of in situ click
reaction and allow the possible use of this strategy for the
discovery of new scaﬀolds useful for the inhibition of the large
family of tyrosine kinases.35−38 The selection of the coupling
partners that have to be incubated with the enzyme can not be
random and must be based on the structure of “hits” originating
from docking studies and/or high-throughput screens. For
example, many of the known inhibitors of TKs could be
dissected in frameworks and properly functionalized with
azide/alkyne moieties to be used as libraries of building blocks
for the in situ click reaction, in the presence of any available
tyrosine kinase. The detection of the favored compounds by
HR-ESI MS will open the way for the preparation and in-depth
biological evaluation of selective molecules as lead structures.
They can be further modiﬁed by substituting the triazole ring
with amide or carbamate groups to modulate the biodispon-
ibility and the biological performance.
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